Safety first
Retatrutide safety & side effects
Retatrutide is an investigational medication. Here is an honest summary of its approval status, the side effects seen in trials, and how to stay safe.
Investigational status — please read
Retatrutide has not been approved by the TGA (Therapeutic Goods Administration) in Australia or the FDA in the United States. It is currently available only through official Eli Lilly clinical trials.
Do not purchase anything claiming to be Retatrutide outside of an official Eli Lilly clinical trial. Unregulated products may contain harmful contaminants, incorrect dosing, or entirely different ingredients. Eli Lilly actively works with law enforcement to combat black-market versions of this drug.
Common side effects observed in trials
These side effects are consistent with other GLP-1-based medications and were generally manageable — most participants continued treatment.
Nausea
The most common side effect, especially early in treatment and during dose increases.
Diarrhoea
Generally mild to moderate and tended to settle as treatment continued.
Constipation
Consistent with other GLP-1-based medications and usually manageable.
Vomiting
Most often occurred early in treatment, alongside nausea.
Dysesthesia
An unusual nerve sensation — generally mild and temporary.
Talk to a professional
Nothing on this website constitutes medical advice. Retatrutide may not be suitable for everyone, and any decision about weight loss treatment should be made with a qualified healthcare professional who knows your medical history. Always consult your GP or specialist before making any decisions about your health or treatment.
Want to know as soon as Retatrutide's safety or approval status changes?
Get updates